|
US6749853B1
(en)
|
1992-03-05 |
2004-06-15 |
Board Of Regents, The University Of Texas System |
Combined methods and compositions for coagulation and tumor treatment
|
|
US5965132A
(en)
|
1992-03-05 |
1999-10-12 |
Board Of Regents, The University Of Texas System |
Methods and compositions for targeting the vasculature of solid tumors
|
|
US6953668B1
(en)
|
1992-11-05 |
2005-10-11 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7070782B1
(en)
*
|
1992-11-05 |
2006-07-04 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen
|
|
US7105159B1
(en)
|
1992-11-05 |
2006-09-12 |
Sloan-Kettering Institute For Cancer Research |
Antibodies to prostate-specific membrane antigen
|
|
US6569432B1
(en)
*
|
1995-02-24 |
2003-05-27 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US7037647B1
(en)
|
1995-02-24 |
2006-05-02 |
Sloan-Kettering Institute For Cancer Research |
Prostate-specific membrane antigen and uses thereof
|
|
US20040253246A1
(en)
*
|
1996-02-23 |
2004-12-16 |
Israeli Ron S. |
Prostate-specific membrane antigen and uses thereof
|
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6150508A
(en)
*
|
1996-03-25 |
2000-11-21 |
Northwest Biotherapeutics, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6962981B1
(en)
*
|
1996-03-25 |
2005-11-08 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
|
US6136311A
(en)
*
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
|
US20060024301A1
(en)
*
|
1997-02-25 |
2006-02-02 |
Corixa Corporation |
Prostate-specific polypeptides and fusion polypeptides thereof
|
|
US6759515B1
(en)
*
|
1997-02-25 |
2004-07-06 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US20060269532A1
(en)
*
|
1997-02-25 |
2006-11-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US6207805B1
(en)
*
|
1997-07-18 |
2001-03-27 |
University Of Iowa Research Foundation |
Prostate cell surface antigen-specific antibodies
|
|
US6232287B1
(en)
*
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
|
US6200765B1
(en)
|
1998-05-04 |
2001-03-13 |
Pacific Northwest Cancer Foundation |
Non-invasive methods to detect prostate cancer
|
|
FR2791573B1
(fr)
*
|
1999-03-30 |
2003-04-11 |
Pf Medicament |
Utilisation d'un extrait de serenoa repens pour la fabrication d'un medicament destine au traitement du cancer de la prostate
|
|
ATE342282T1
(de)
*
|
1999-07-29 |
2006-11-15 |
Medarex Inc |
Humane monoklonale antikörper gegen prostata spezifisches membranantigen
|
|
EP1710256A1
(en)
*
|
1999-07-29 |
2006-10-11 |
Medarex, Inc. |
Human monoclonal antibodies to prostate specific membrane antigen
|
|
WO2001019956A2
(en)
*
|
1999-09-13 |
2001-03-22 |
Bander Neil H |
A method for isolation of prostatic epithelial cells from semen
|
|
US20080153119A1
(en)
*
|
1999-09-24 |
2008-06-26 |
Schebo Biotech Ag |
Detecting the presence of pyruvate kinase isoenzyme in feces
|
|
EP2343047B2
(en)
|
2000-02-08 |
2021-03-17 |
Rice University |
Optically-active nanoparticles for use in therapeutic and diagnostic methods
|
|
US6379550B1
(en)
*
|
2000-07-24 |
2002-04-30 |
Health Research, Inc. |
Method for detecting PSA and its molecular forms using thiophilic gel
|
|
US7048931B1
(en)
|
2000-11-09 |
2006-05-23 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
AU2002239403A1
(en)
*
|
2000-12-01 |
2002-06-11 |
The Johns Hopkins University |
Tissue specific prodrugs
|
|
WO2002096460A1
(en)
*
|
2001-05-30 |
2002-12-05 |
Cornell Research Foundation, Inc. |
Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
|
|
JP4619651B2
(ja)
*
|
2001-06-01 |
2011-01-26 |
コーネル・リサーチ・ファンデーション・インコーポレイテッド |
前立腺特異的膜抗原に対する修飾抗体およびその使用
|
|
US7666414B2
(en)
*
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
|
US7514078B2
(en)
*
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
|
US20060073530A1
(en)
*
|
2001-08-15 |
2006-04-06 |
Olaf Schneewind |
Methods and compositions involving sortase B
|
|
AU2002359244A1
(en)
*
|
2001-09-05 |
2003-04-28 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of |
Imaging the activity of extracellular proteases in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases
|
|
AU2002305767B2
(en)
*
|
2001-09-20 |
2008-04-10 |
Cornell Research Foundation, Inc. |
Methods and compositions for treating and preventing skin disorders using binding agents specific for PSMA
|
|
WO2003028840A2
(en)
*
|
2001-09-27 |
2003-04-10 |
Board Of Regents, The University Of Texas System |
Combined compositions and methods for tumor vasculature coagulation and treatment
|
|
ES2606537T3
(es)
*
|
2001-10-23 |
2017-03-24 |
Psma Development Company L.L.C. |
Anticuerpos contra PSMA
|
|
US20050215472A1
(en)
*
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
|
US20040161776A1
(en)
*
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US7767803B2
(en)
*
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
|
KR20110025885A
(ko)
|
2002-07-15 |
2011-03-11 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
포스파티딜에탄올아민에 결합하는 펩타이드, 및 바이러스 감염을 치료하는데 있어서 이의 용도
|
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
|
DE60323677D1
(de)
*
|
2003-01-10 |
2008-10-30 |
Millennium Pharm Inc |
Verfahren zur bestimmung des wiederauftretens von prostata krebs
|
|
EP1587837B1
(en)
*
|
2003-01-28 |
2012-06-13 |
Proscan RX Pharma Inc. |
Epitope sequences for prostate cancer diagnosis and treatment
|
|
WO2005094882A1
(en)
*
|
2004-03-03 |
2005-10-13 |
Millennium Pharmaceuticals, Inc. |
Modified antibodies to prostate-specific membrane antigen and uses thereof
|
|
WO2005092286A2
(en)
*
|
2004-03-29 |
2005-10-06 |
The University Of Houston System |
Metallic nano-particles and discrete polymer-coated nano-particles
|
|
WO2005100404A1
(en)
*
|
2004-04-19 |
2005-10-27 |
Proscan Rx Pharma |
Prostate cancer diagnosis and treatment
|
|
WO2006051542A1
(en)
*
|
2004-11-12 |
2006-05-18 |
Kpe Ltd. |
Nanoparticle mediated ultrasound therapy and diagnostic imaging
|
|
EP1864134A4
(en)
*
|
2005-02-07 |
2010-10-20 |
Univ Columbia |
METHOD FOR TREATING OR PREVENTING HORMONRESISTENT PROSTATE CANCER USING PROTOCADHERINE PC SPECIFIC SIRNA OR OTHER INHIBITORS OF PROTOCADHERINE PC EXPRESSION OR ACTIVITY
|
|
JP2008529556A
(ja)
*
|
2005-02-18 |
2008-08-07 |
メダレックス， インク． |
前立腺特異的膜抗原（ｐｓｍａ）に対するヒトモノクローナル抗体
|
|
WO2006089231A2
(en)
*
|
2005-02-18 |
2006-08-24 |
Medarex, Inc. |
Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
|
|
WO2006096754A2
(en)
*
|
2005-03-07 |
2006-09-14 |
Archemix Corp. |
Stabilized aptamers to psma and their use as prostate cancer therapeutics
|
|
EP1726650A1
(en)
*
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
US7736647B2
(en)
*
|
2005-06-15 |
2010-06-15 |
Monoclonal Antibodies Therapeutics |
Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
|
|
US20070160617A1
(en)
*
|
2005-06-20 |
2007-07-12 |
Psma Development Company, Llc |
PSMA antibody-drug conjugates
|
|
CA2623236A1
(en)
*
|
2005-09-26 |
2007-04-05 |
Medarex, Inc. |
Human monoclonal antibodies to cd70
|
|
KR101624587B1
(ko)
*
|
2005-12-20 |
2016-05-26 |
에스비아이 바이오테크 가부시키가이샤 |
항-ｉｌｔ7 항체
|
|
CN101622276B
(zh)
*
|
2006-07-18 |
2015-04-22 |
赛诺菲-安万特 |
用于治疗癌症的抗epha2的拮抗抗体
|
|
US20100150950A1
(en)
*
|
2006-12-14 |
2010-06-17 |
Medarex, Inc. |
Human antibodies that bind cd70 and uses thereof
|
|
WO2009015263A2
(en)
*
|
2007-07-25 |
2009-01-29 |
Wyeth |
Methods for characterizing cell proximity
|
|
EP2740490A1
(en)
|
2007-10-03 |
2014-06-11 |
Cornell University |
Treatment of proliferative disorders using antibodies to PSMA
|
|
EP2281004A4
(en)
*
|
2008-04-14 |
2012-02-15 |
Proscan Rx Pharma Inc |
PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
|
|
EP2727606A3
(en)
|
2008-09-08 |
2015-09-23 |
Psma Development Company, L.L.C. |
Compounds for killing psma-expressing, taxane-resistant cancer cells
|
|
US20100082438A1
(en)
*
|
2008-10-01 |
2010-04-01 |
Ronnie Jack Garmon |
Methods and systems for customer performance scoring
|
|
MD24Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
|
|
MD23Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
|
|
MD36Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
|
|
MD35Z
(ro)
*
|
2008-12-02 |
2010-01-31 |
Василе ЖОВМИР |
Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
|
|
HRP20230487T1
(hr)
|
2009-02-13 |
2023-07-21 |
Immunomedics, Inc. |
Imunokonjugati s unutarstaničnom vezom koja se može rascijepiti
|
|
EP2398504B1
(en)
|
2009-02-17 |
2018-11-28 |
Cornell Research Foundation, Inc. |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
|
AU2010249719A1
(en)
|
2009-05-19 |
2012-05-31 |
Aic Blab Company |
Composite current collector and methods therefor
|
|
US8221753B2
(en)
|
2009-09-30 |
2012-07-17 |
Tracon Pharmaceuticals, Inc. |
Endoglin antibodies
|
|
CA2782194C
(en)
|
2009-12-02 |
2018-01-16 |
Immunomedics, Inc. |
Combination of radiolabelled antibodies (rait) and antibody-drug conjugates (adc) for treatment of pancreatic cancer
|
|
US8772459B2
(en)
|
2009-12-02 |
2014-07-08 |
Imaginab, Inc. |
J591 minibodies and Cys-diabodies for targeting human prostate specific membrane antigen (PSMA) and methods for their use
|
|
ES2621874T3
(es)
|
2010-03-26 |
2017-07-05 |
Memorial Sloan-Kettering Cancer Center |
Anticuerpos para MUC16 y métodos de uso de los mismos
|
|
JP5702944B2
(ja)
*
|
2010-03-31 |
2015-04-15 |
独立行政法人国立がん研究センター |
バイオマーカー
|
|
US9133239B2
(en)
|
2010-04-20 |
2015-09-15 |
The Research Foundation For The State University Of New York |
Compositions and methods for inhibiting matrix metalloproteinase (MMP)-mediated cell migration
|
|
EP2567234B1
(en)
*
|
2010-05-07 |
2018-09-19 |
F.Hoffmann-La Roche Ag |
Diagnostic method for the detection of cells ex vivo
|
|
WO2012075173A2
(en)
|
2010-12-01 |
2012-06-07 |
Board Of Regents The University Of Texas System |
Compositions and method for deimmunization of proteins
|
|
WO2012106368A2
(en)
|
2011-01-31 |
2012-08-09 |
The Regents Of The University Of California |
Methods for inhibiting prostate cancer
|
|
US8314566B2
(en)
*
|
2011-02-22 |
2012-11-20 |
Quarkstar Llc |
Solid state lamp using light emitting strips
|
|
JP6024025B2
(ja)
|
2011-05-02 |
2016-11-09 |
イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． |
少容量投与用のアロタイプ選択抗体の限外濾過濃縮
|
|
EP2858676B1
(en)
|
2012-06-07 |
2019-03-13 |
Ambrx, Inc. |
Prostate-specific membrane antigen antibody drug conjugates
|
|
WO2013188740A1
(en)
|
2012-06-14 |
2013-12-19 |
Ambrx, Inc. |
Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
UA115789C2
(uk)
|
2012-09-05 |
2017-12-26 |
Трейкон Фармасутікалз, Інк. |
Композиція антитіла до cd105 та її застосування
|
|
HK1211967A1
(zh)
*
|
2012-10-05 |
2016-06-03 |
Cornell University |
雄激素抑制，前列腺特异性膜抗原和有条件增强漏洞状态的概念
|
|
HUE045435T2
(hu)
|
2012-10-12 |
2019-12-30 |
Medimmune Ltd |
Pirrolobenzodiazepinek és konjugátumaik
|
|
PL2900277T3
(pl)
|
2012-12-13 |
2022-05-16 |
Immunomedics, Inc. |
Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
|
|
US11242399B2
(en)
|
2013-02-19 |
2022-02-08 |
Adienne S.A. |
Anti-CD26 antibodies
|
|
JP6444902B2
(ja)
|
2013-03-13 |
2018-12-26 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びその結合体
|
|
DK2968503T3
(en)
|
2013-03-15 |
2018-12-03 |
Intrinsic Lifesciences Llc |
ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
|
|
JP6908964B2
(ja)
|
2013-10-18 |
2021-07-28 |
ピーエスエムエー ディベロップメント カンパニー，エルエルシー |
Ｐｓｍａリガンドコンジュゲートによる併用療法
|
|
WO2015073896A2
(en)
|
2013-11-15 |
2015-05-21 |
Psma Development Company, Llc |
Biomarkers for psma targeted therapy for prostate cancer
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
US9139649B2
(en)
|
2014-02-25 |
2015-09-22 |
Immunomedics, Inc. |
Humanized anti-CD22 antibody
|
|
JP6517240B2
(ja)
|
2014-05-22 |
2019-05-22 |
シントン・バイオファーマシューティカルズ・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｂ．Ｖ． |
抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるａｄｃ
|
|
WO2015200260A1
(en)
|
2014-06-24 |
2015-12-30 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
JP6531166B2
(ja)
|
2014-09-10 |
2019-06-12 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピン及びそのコンジュゲート
|
|
EP3197915A4
(en)
|
2014-09-22 |
2018-12-19 |
Intrinsic Lifesciences LLC |
Humanized anti-hepcidin antibodies and uses thereof
|
|
AU2015328370B2
(en)
|
2014-10-07 |
2021-08-05 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
CA2966905A1
(en)
|
2014-11-12 |
2016-05-19 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
US9926375B2
(en)
|
2014-11-12 |
2018-03-27 |
Tracon Pharmaceuticals, Inc. |
Anti-endoglin antibodies and uses thereof
|
|
CN104447955B
(zh)
*
|
2014-11-23 |
2018-04-20 |
南京市第一医院 |
一种与psma膜外区靶向性结合的多肽及其应用
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
MX391249B
(es)
|
2015-03-17 |
2025-03-21 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos anti-muc16 y sus usos.
|
|
US10722523B2
(en)
|
2015-03-17 |
2020-07-28 |
The Regents Of The University Of California |
Chemoimmunotherapy for epithelial cancer
|
|
CA2981543A1
(en)
|
2015-04-22 |
2016-10-27 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
|
|
CN111234027A
(zh)
|
2015-05-21 |
2020-06-05 |
哈普恩治疗公司 |
三特异性结合蛋白质及使用方法
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
|
ES3020458T3
(en)
|
2015-08-07 |
2025-05-22 |
Imaginab Inc |
Antigen binding constructs to target molecules
|
|
EP3192810A1
(en)
*
|
2016-01-14 |
2017-07-19 |
Deutsches Krebsforschungszentrum |
Psma binding antibody and uses thereof
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
CN109641046B
(zh)
|
2016-05-20 |
2023-11-07 |
哈普恩治疗公司 |
单链可变片段cd3结合蛋白质
|
|
BR112018073739A2
(pt)
|
2016-05-20 |
2019-02-26 |
Harpoon Therapeutics, Inc. |
proteína de ligação de albumina sérica de domínio único
|
|
CN109311996B
(zh)
|
2016-06-06 |
2023-11-28 |
阿布泽纳(英国)有限公司 |
抗体、其用途及其缀合物
|
|
GB201614162D0
(en)
|
2016-08-18 |
2016-10-05 |
Polytherics Ltd |
Antibodies, uses thereof and conjugates thereof
|
|
JP2019534882A
(ja)
|
2016-10-11 |
2019-12-05 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
免疫介在性療法薬を有する抗体−薬物コンジュゲート
|
|
JP7215997B2
(ja)
|
2016-11-23 |
2023-01-31 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原（ｐｓｍａ）を標的とする三重特異性タンパク質と使用方法
|
|
JP6812551B2
(ja)
|
2016-11-23 |
2021-01-13 |
ハープーン セラピューティクス，インク． |
前立腺特異的膜抗原結合タンパク質
|
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
CA3063359A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
|
CA3063362A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Msln targeting trispecific proteins and methods of use
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
UA129446C2
(uk)
|
2017-10-13 |
2025-04-30 |
Гарпун Терап'Ютікс, Інк. |
Триспецифічні білки і способи їх застосування
|
|
EP3703886A4
(en)
|
2017-11-04 |
2021-05-05 |
Sona Nanotech |
METAL NANOPARTICLES AND METHOD FOR MANUFACTURING THEREOF
|
|
AU2019231205A1
(en)
|
2018-03-06 |
2020-09-24 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
LT3773910T
(lt)
*
|
2018-03-29 |
2024-09-25 |
Ambrx, Inc. |
Humanizuoto antikūno prieš prostatai specifinį membraninį antigeną (psma) konjugatai su vaistu
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
CA3098103A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
EP3587454A1
(en)
*
|
2018-06-27 |
2020-01-01 |
Albert-Ludwigs-Universität Freiburg |
Chimeric antigen receptors that bind to prostate specific membrane antigen
|
|
FI3830132T3
(fi)
|
2018-07-31 |
2023-01-13 |
|
Humanisoituja vasta-aineita psma:ta vastaan
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
EP3856771A4
(en)
|
2018-09-25 |
2022-06-29 |
Harpoon Therapeutics, Inc. |
Dll3 binding proteins and methods of use
|
|
USD925928S1
(en)
|
2019-03-01 |
2021-07-27 |
Simplehuman, Llc |
Vanity mirror
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
CN116390772A
(zh)
|
2020-07-07 |
2023-07-04 |
博泰康医药公司 |
新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
|
|
WO2022079211A1
(en)
|
2020-10-16 |
2022-04-21 |
Adc Therapeutics Sa |
Glycoconjugates
|
|
CN112285082A
(zh)
*
|
2020-10-28 |
2021-01-29 |
上海睿钰生物科技有限公司 |
一种基于细胞直径评价细胞杀伤效力的方法及其应用
|
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
|
US20250073349A1
(en)
|
2021-05-10 |
2025-03-06 |
Kawasaki Institute Of Industrial Promotion |
Antibody having reduced binding affinity for antigen
|
|
CA3236930A1
(en)
|
2021-11-03 |
2022-04-21 |
Hangzhou Dac Biotech Co., Ltd. |
Specific conjugation of an antibody
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|